ASH 2018 | A new era for elderly AML patients
Acute myeloid leukemia (AML) has a median age of diagnosis of around 68 years; however, patients who are ineligible for intensive induction chemotherapy have few therapeutic options. Here, Farhad Ravandi-Kashani, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase Ib trial (NCT02203773) studying the safety and efficacy of venetoclax in combination with hypomethylating agents for patients with AML who are ineligible for intensive chemotherapy. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Farhad discusses the encouraging data, suggesting that this combination may provide a potent therapeutic approach for elderly patients with AML.
Get great new content delivered to your inboxSign up